Major Depressive Disorder (MDD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Major Depressive Disorder (MDD) Market Outlook

Thelansis's "Major Depressive Disorder (MDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Major Depressive Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Major Depressive Disorder (MDD) Overview

Major Depressive Disorder (MDD) is a common and serious psychiatric condition characterized by persistent low mood, anhedonia (loss of interest or pleasure), and functional impairment lasting at least two weeks. It affects individuals across all age groups and is driven by a complex interplay of genetic, neurobiological, psychological, and environmental factors.

Clinically, MDD presents with a broad spectrum of symptoms, including fatigue, sleep disturbances, appetite changes, impaired concentration, and feelings of guilt or worthlessness, with severe cases associated with suicidal ideation or behavior.

Diagnosis is clinical and based on standardized criteria such as DSM-5, with careful exclusion of other psychiatric or medical conditions. The disorder is highly heterogeneous, with variability in severity, recurrence, and treatment response.

Management is multimodal and includes:

• Psychotherapy (primarily cognitive behavioral therapy)
• Pharmacotherapy (SSRIs, SNRIs, and other antidepressants)
• Lifestyle and supportive interventions

Despite the availability of multiple treatment options, a significant proportion of patients experience treatment resistance or incomplete response, highlighting substantial unmet need.

Key Highlights

• The diagnosed MDD population in France is large and relatively stable, increasing from ~4.43 million in 2025 to ~4.59 million by 2035, reflecting a low growth rate (~0.4% CAGR).
• A considerable proportion of patients fall into the treatment-resistant depression (TRD) category (~20-30%), driving demand for advanced therapies.
• The treatment landscape remains highly generic-driven, with:
• SSRIs and SNRIs as first-line therapies (~60-70% share)
• Widespread use of adjunct therapies (antipsychotics, mood stabilizers)

Market Overview

• The MDD market in Germany is projected to grow from ~$240M in 2025 to ~$565M by 2035, reflecting a strong CAGR of ~8-9%.
• The diagnosed population in Italy shows minimal growth (~0.4% CAGR), indicating:
• Stable disease prevalence
• Market growth driven more by treatment innovation than patient expansion

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Biohaven Therapeutics Ltd.
• Cybin IRL Limited
• Xenon Pharmaceuticals Inc.
• Neurocrine Biosciences
• Biogen
• Eli Lilly and Company
• AbbVie
• Axsome Therapeutics, Inc.
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Neumora Therapeutics, Inc.
• Engrail Therapeutics INC
• Janssen-Cilag Ltd.
• Autobahn Therapeutics, Inc.
• Navitor Pharmaceuticals, Inc.
• Takeda
• Syndeio Biosciences, Inc
• Suven Life Sciences Limited
• Definium Therapeutics US, Inc.
• Boehringer Ingelheim
• Relmada Therapeutics, Inc.
• Sirtsei Pharmaceuticals, Inc.
• Intra-Cellular Therapies, Inc.
• COMPASS Pathways
• Beijing Greatway Pharmaceutical Technology Co.,Ltd.
• Bausch Health Americas, Inc.
• Alto Neuroscience
• Gilgamesh Pharmaceuticals
• BioLite, Inc.
• Luye Pharma Group Ltd.
• Vigonvita Life Sciences
• Draig Therapeutics Ltd
• Supernus Pharmaceuticals, Inc.
• Ono Pharmaceutical Co. Ltd
• CSPC Ouyi Pharmaceutical Co., Ltd.
• Zhejiang Huahai Pharmaceutical Co., Ltd.
• Chengdu Kanghong Pharmaceutical Group Co., Ltd.
• Vanda Pharmaceuticals
• Seaport Therapeutics
• Jiangsu Nhwa Pharmaceutical Co., Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Sichuan Purity Pharmaceutical Technology Co., Ltd.
• ACADIA Pharmaceuticals Inc.
• Corium Innovations, Inc.